First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the past, treatment for malignant ascites focussed on symptomatic relief or treatment of the underlying disease. A promising option evolved with catumaxomab (Removab®) in 2009. Since catumaxomab is a bispecific, trifunctional antibody with mouse-rat origin, so far repeated treatment cycles were not an option due to the occurrence of human anti-drug antibodies (HADA). Nevertheless, the good results obtained so far raised the question whether a repeated treatment cycle with catumaxomab could be feasible and effective. We report on a 74-year-old female patient with breast cancer and peritoneal carcinomatosis. To our knowledge, this is the first patient world-wide to be treated with a repeated cycle of catumaxomab. HAMA (human anti-mouse antibodies) values were identified in blood and ascites samples. Ascites samples were also stained to identify and quantify cells, positive for EpCAM (epithelial cell adhesion molecule) and CD45. The patient tolerated the second cycle without unexpected side effects and remained puncture-free for another 45 days. Analysis of blood and ascites revealed a quick increase in HAMA values in the blood samples after 1 week, but considerably lower HAMA values and delayed increase in the ascites samples. Also a distinct and continuous decrease of EpCAM-positive cells was observed in the ascites samples under treatment. A strong increase in CD45-positive cells was detected after the beginning of the second cycle, with a consecutive decline toward the end. This first experience suggests that a repeated cycle of catumaxomab might be feasible and effective. As a consequence, a phase II trial (SECIMAS) was initiated.
- Aslam N, Marino C. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7. CrossRef
- Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999–1011. CrossRef
- Parsons S, Murawa P, Koralewski P. Intraperitoneal treatment of malignant ascites due to epithelial tumours with catumaxomab. a phase II/III study. J Clin Oncol. 2008;28:3000.
- Heiss M, Murawa P, Koralewski P, Kolesnik O, Ivanchenko V, Dudnichenko A, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010 (Epub ahead of print).
- Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8):2526–34. CrossRef
- Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261–6. CrossRef
- Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999;163(3):1246–52.
- Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM Ã—anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899–905. CrossRef
- Heiss M, Ströhlein M, Jäger M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005;117(3):435–43. CrossRef
- Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97(3):315–21. CrossRef
- First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report
Volume 29, Issue 2 , pp 1391-1396
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Trifunctional antibody
- Peritoneal carcinomatosis
- Repeated cycle
- Industry Sectors
- Author Affiliations
- 1. Charité-Campus Virchow Klinikum, Department for Gynecology and Obstetrics, University Medicine of Berlin, European Competence Center for Ovarian Cancer (EKZE), Augustenburger Platz 1, 13353, Berlin, Germany
- 2. TRION Research GmbH, Am Klopferspitz 19, 82152, Martinsried, Germany
- 3. TRION Pharma GmbH, Frankfurter Ring 193a, 80807, München, Germany